Articles mentioning both Takeda and Shire -BoardProspects

Articles mentioning both Takeda and Shire

1-9 of 9
1. François Nader, MD, Joins Moderna's Board of Directors
  
  Explore businesswire.com Dec 10 2019 BoardMoves
  
  ...oss development, regulatory affairs and commercial at NPS Pharmaceuticals (acquired by Shire Plc, now part of Takeda (NYSE: TAK)), as well as Aventis-Pharma and the Pasteur Vaccines division of Rhone-Poulenc, now both pa...
  Read Full Article
  
  Comment
  
  Mentions: Investor Relations Leadership Sanofi
2. Phathom Pharmaceuticals Announces Leadership Succession Plan and Strengthens Board of Directors with New Appointments
  
  Explore businesswire.com Sep 27 2019 BoardMoves
  
  ...he Board of Directors at Sage Therapeutics and Vanda Pharmaceuticals. Mr. Slavinsky serves as Vice President, Takeda Center for External Innovation and Head, Gastroenterology Business Development, Externalization and Spe...
  Read Full Article
  
  Comment
  
  Mentions: Leadership Succession General Motors
3. Health Insurer Centene is Buying Rival WellCare in a $17.3 Billion Deal as the Healthcare Dealmaking Frenzy Continues
  
  Explore Business Insider Mar 27 2019 BoardNews
  
  ...ecord high. Last year proved to be a record in healthcare dealmaking, including monster deals like Takeda and Shire's $59 billion merger and Cigna's $67 billion Express Scripts acquisition. The industry's sweeping consol...
  Read Full Article
  
  Comment
  
  Mentions: acquisition Cigna Express Scripts
4. Bristol-Myers Squibb has $2.2 Billion at Stake if its Deal to Acquire Celgene Falls Apart, and Opposition is Mounting
  
  Explore Business Insider Feb 28 2019 BoardNews
  
  ...eal is the largest ever in pharma, topping Pfizer's 1999 acquisition of Warner-Lambert and last year's Takeda-Shire deal, according to Bloomberg News. If the deal goes through, Bristol-Myers Squibb and Celgene will go fr...
  Read Full Article
  
  Comment
  
  Mentions: Investment Management State Street
5. Takeda Pushes Back as Group Seeks to Stop $62 Billion Shire Deal
  
  Explore BNN Bloomberg Nov 6 2018 BoardNews
  
  ... of March, Shire’s stock has gained 47 percent. Shire shares slipped 0.1 percent in London trading on Monday. Takeda last week said Weber’s management team informed the board of its interest in Shire as early as Septembe...
  Read Full Article
  
  Comment
  
  Mentions: Takeover acquisition Japan
6. Japan's Takeda Seals $62 Billion Takeover of Adderall Maker Shire
  
  Explore Business Insider May 8 2018 BoardNews
  
  ...ure a recommendation. Shire investors will receive $30.33 in cash and either 0.839 new Takeda shares or 1.678 Takeda ADSs for each share, the companies said, valuing the offer at £48.17 a share based on the latest price ...
  Read Full Article
  
  Comment
  
  Mentions: Takeover acquisition Japan
7. Activists to Take Center Stage as Annual Meetings Get Under Way
  
  Explore Yahoo! Finance Apr 24 2018 BoardNews
  
  ...rs gather in Dublin today to elect board members and vote on pay, but the talk of the meeting is likely to be Takeda Pharmaceutical Co.’s tentative bid for the company of more than $60 billion. Activist activity is up th...
  Read Full Article
  
  Comment
  
  Mentions: Investment Management Google
8. 'Losing direction': Allergan Investors are Unhappy After a Wild 4 Hour Takeover Drama
  
  Explore Business Insider Apr 19 2018 BoardNews
  
  ...r $50 billion Adderall-maker Shire. Four hours later, Allergan said that it does not intend to make a bid for Shire, stalling out a potential bidding war over the company with Japan's Takeda. Allergan's stock dropped 8% ...
  Read Full Article
  
  Comment
  
  Mentions: Takeover Nasdaq Japan
9. Allergan and Takeda May Fight Over Shire
  
  Explore The New York Times Apr 19 2018 BoardNews
  
  ...se disclosures on Thursday, Allergan said in a statement that it too was weighing a bid for Shire. Takeda and Shire said that they are in discussions, which could lead to yet another revised bid. Yet for both Takeda and ...
  Read Full Article
  
  Comment
  
  Mentions: Management I.P.O. Credit Suisse
10. 1-9 of 9